Trial Profile
Open label, phase I/II study of combination of lenalidomide, cyclophosphamide and prednisone in patients with relapsed and refractory multiple myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 25 Nov 2015
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Lenalidomide (Primary) ; Prednisone (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celgene Corporation
- 25 Nov 2015 New trial record